| Website | crownbio.com |
| Category | BioTech |
| Phone | 603-583-4408 |
| Employees |
| TOTAL | $28.8M |
| FUNDING TOTAL | $28.8M |
| Series C, 5/11 OrbiMed Advisors Argonaut Private Equity CID Group QiMing Venture Partners | $28.8M |
Crown Bioscience has established multiple in vivo assay systems to evaluate novel anti-cancer compounds. Each assay is designed to understand specific aspects of drug property and its mechanism of action. By accessing their comprehensive capability, their customers can advance development programs in a timely and cost-effective manner. Their highly experienced preclinical team is; focused solely on oncology, works with you to choose the most appropriate study design and screening method for an investigational agent.
